Indeed, TNF blockade fails or even exacerbates disease activity in TNF-driven pathologies, such as MS or heart failure, and significant patient numbers do not respond in approved applications where TNF blockers demonstrated high clinical efficacy 4,5. This evidence concerns the gene TNF and myeloid sarcoma.